Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives

American Journal of Hematology

Volumn 60, Issue 3, 1999, Pages 175-180

  Harris, Geoffrey M ^b   Stendt, Caroline L ^b   Vollenhoven, Beverley J ^b   Gan, T Eng ^b   Tipping, Peter G ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b NONE

Author keywords

Coagulation; Factor VIIa; Lipoprotein; Oral contraceptive; Prothrombin; Thrombosis; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 7A; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; FEMALE; HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS;

AUSTRALIA; BIOLOGY; BLOOD COAGULATION EFFECTS--WOMEN; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; FAMILY PLANNING; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; OCEANIA; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, COMBINED; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; RISK FACTORS; THROMBOEMBOLISM; THROMBOSIS--WOMEN; VASCULAR DISEASES; WOMEN;

ADOLESCENT; ADULT; BLOOD COAGULATION; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DOWN-REGULATION; FACTOR VIIA; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PROTHROMBIN; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 0033014691     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X     Document Type: Article

References (29)

1. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575.
2. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83.
3. Bokarewa MI, Falk G, Sten-Linder M, Egberg N, Blombäck M, Bremme K. Thrombotic risk factors and oral contraception. J Lab Clin Med 1995;126:294.
4. Bottinger LE, Boman G, Eklunk G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;i:1097.
5. Meade TW, Greenberg G, Thompson SG. Progersterones and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of the 50 and 30 μg oestrogen preparations. Br Med J 1980;280:1157.
6. Royal College of General Practitioners' Oral Contraceptive Study. Further analysis of mortality in oral contraceptive users. Lancet 1981;i: 541.
7. Speroff L, De Cherney A, and the Advisory Board for New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynaecol 1993;81:1034.
8. Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraceptive. Br J Haematol 1988;68:437.
9. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992;29:170.
10. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Haematol 1992;29:159.
11. Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIC associated with decreases tissue factor pathway inhibitor and increased plasminogen activator inhibitor-I in dyslipidemias. Arterioscler Thromb Vasc Biol 1996;16:77.
12. Jespersen J, Petersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990;163:396.
13. Ariens RA, Coppola R, Potenza I, Mannucci PM. The increase with age of the components of the tissue factor coagulation pathway is gender dependent. Blood Coagul Fibrinolysis 1995;6:433.
14. Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K, Kato H. Decreased plasma tissue factor pathway inhibitor activity in stroke patients. Thromb Haemost 1995;74:1050.
15. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995;73:10.
16. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;52:165.
17. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal human population and relation to cholesterol. Blood Coagul Fibrinolysis 1992;2:713.
18. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1&2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153.
19. Morrisey JH, Macik BG, Neuenschwander PT, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activity. Blood 1993;81: 734.
20. Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961;58:477.
21. Seligsohn U, Kasper CK, Osterud, Rapaport SI. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979;53:828.
22. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55:638.
23. Kondo S, Kisiel W. Regulation of factor VIIa activity in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromb Res 1987;46:325.
24. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992;79:3219.
25. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988;50:803.
26. Krauss RM, Burkman RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992;167:1177.
27. Wahl P, Walden C, Knopp R, Hoover J. Effect of oestrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862.
28. Narita M, Bu G, Olins GM, Higichi DA, Herz J, Broze GJ Jr, Schwartz AL. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 1995;270:24800.
29. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995;95:177.